Cargando…
Prognostic Value of Tissue Inhibitor of Metalloproteinase-2 Expression in Patients with Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
BACKGROUND AND OBJECTIVES: Tissue inhibitor of metalloproteinase-2 (TIMP-2) is a small secretory glycoprotein with anti–matrix metalloproteinase activity. Data on the value of TIMP-2 as a prognostic factor in non–small cell lung cancer (NSCLC) are discordant and remain controversial. A systematic re...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408055/ https://www.ncbi.nlm.nih.gov/pubmed/25905787 http://dx.doi.org/10.1371/journal.pone.0124230 |
_version_ | 1782368009454616576 |
---|---|
author | Zhu, Lin Yu, Hong Liu, Shi-Yuan Xiao, Xiang-Sheng Dong, Wei-Hua Chen, Yi-Nan Xu, Wei Zhu, Tong |
author_facet | Zhu, Lin Yu, Hong Liu, Shi-Yuan Xiao, Xiang-Sheng Dong, Wei-Hua Chen, Yi-Nan Xu, Wei Zhu, Tong |
author_sort | Zhu, Lin |
collection | PubMed |
description | BACKGROUND AND OBJECTIVES: Tissue inhibitor of metalloproteinase-2 (TIMP-2) is a small secretory glycoprotein with anti–matrix metalloproteinase activity. Data on the value of TIMP-2 as a prognostic factor in non–small cell lung cancer (NSCLC) are discordant and remain controversial. A systematic review and meta-analysis was performed to explore this issue. METHODS: We identified the relevant literature by searching the PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure, SinoMed, and Wanfang Data databases (search terms: “non-small cell lung cancer” or “NSCLC” or “Lung Carcinoma, Non-Small-Cell”, “Tissue Inhibitor of Metalloproteinase-2” or “TIMP-2”, and “prognosis” or “prognostic” or “survive”) for updates prior to March 1, 2014. The pooled hazard ratio (HR) of overall survival with a 95% confidence interval (95% CI) was used to evaluate the strength of the association between positive TIMP-2 expression and survival in patients with NSCLC. RESULTS: We included 12 studies in our systematic review; five studies involving 399 patients with NSCLC were meta-analyzed. The pooled HR of all included patients was 0.57 (95% CI: 0.43–0.77), and the HRs of subgroup analysis according to stage (I–IV), testing method (immunohistochemistry) and high TIMP-2 expression percentage (<50%) were 0.63 (95% CI: 0.43–0.92), 0.55 (95% CI: 0.41–0.74), and 0.50 (95% CI: 0.28–0.88), respectively. These data suggested that high TIMP-2 expression is associated with favorable prognosis in NSCLC. The meta-analysis did not reveal heterogeneity or publication bias. CONCLUSIONS: TIMP-2 expression indicates favorable prognosis in patients with NSCLC; as a protective factor, it could help predict outcome and may guide clinical therapy in the future. |
format | Online Article Text |
id | pubmed-4408055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-44080552015-05-04 Prognostic Value of Tissue Inhibitor of Metalloproteinase-2 Expression in Patients with Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Zhu, Lin Yu, Hong Liu, Shi-Yuan Xiao, Xiang-Sheng Dong, Wei-Hua Chen, Yi-Nan Xu, Wei Zhu, Tong PLoS One Research Article BACKGROUND AND OBJECTIVES: Tissue inhibitor of metalloproteinase-2 (TIMP-2) is a small secretory glycoprotein with anti–matrix metalloproteinase activity. Data on the value of TIMP-2 as a prognostic factor in non–small cell lung cancer (NSCLC) are discordant and remain controversial. A systematic review and meta-analysis was performed to explore this issue. METHODS: We identified the relevant literature by searching the PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure, SinoMed, and Wanfang Data databases (search terms: “non-small cell lung cancer” or “NSCLC” or “Lung Carcinoma, Non-Small-Cell”, “Tissue Inhibitor of Metalloproteinase-2” or “TIMP-2”, and “prognosis” or “prognostic” or “survive”) for updates prior to March 1, 2014. The pooled hazard ratio (HR) of overall survival with a 95% confidence interval (95% CI) was used to evaluate the strength of the association between positive TIMP-2 expression and survival in patients with NSCLC. RESULTS: We included 12 studies in our systematic review; five studies involving 399 patients with NSCLC were meta-analyzed. The pooled HR of all included patients was 0.57 (95% CI: 0.43–0.77), and the HRs of subgroup analysis according to stage (I–IV), testing method (immunohistochemistry) and high TIMP-2 expression percentage (<50%) were 0.63 (95% CI: 0.43–0.92), 0.55 (95% CI: 0.41–0.74), and 0.50 (95% CI: 0.28–0.88), respectively. These data suggested that high TIMP-2 expression is associated with favorable prognosis in NSCLC. The meta-analysis did not reveal heterogeneity or publication bias. CONCLUSIONS: TIMP-2 expression indicates favorable prognosis in patients with NSCLC; as a protective factor, it could help predict outcome and may guide clinical therapy in the future. Public Library of Science 2015-04-23 /pmc/articles/PMC4408055/ /pubmed/25905787 http://dx.doi.org/10.1371/journal.pone.0124230 Text en © 2015 Zhu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Zhu, Lin Yu, Hong Liu, Shi-Yuan Xiao, Xiang-Sheng Dong, Wei-Hua Chen, Yi-Nan Xu, Wei Zhu, Tong Prognostic Value of Tissue Inhibitor of Metalloproteinase-2 Expression in Patients with Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis |
title | Prognostic Value of Tissue Inhibitor of Metalloproteinase-2 Expression in Patients with Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis |
title_full | Prognostic Value of Tissue Inhibitor of Metalloproteinase-2 Expression in Patients with Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis |
title_fullStr | Prognostic Value of Tissue Inhibitor of Metalloproteinase-2 Expression in Patients with Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Prognostic Value of Tissue Inhibitor of Metalloproteinase-2 Expression in Patients with Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis |
title_short | Prognostic Value of Tissue Inhibitor of Metalloproteinase-2 Expression in Patients with Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis |
title_sort | prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non–small cell lung cancer: a systematic review and meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408055/ https://www.ncbi.nlm.nih.gov/pubmed/25905787 http://dx.doi.org/10.1371/journal.pone.0124230 |
work_keys_str_mv | AT zhulin prognosticvalueoftissueinhibitorofmetalloproteinase2expressioninpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT yuhong prognosticvalueoftissueinhibitorofmetalloproteinase2expressioninpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT liushiyuan prognosticvalueoftissueinhibitorofmetalloproteinase2expressioninpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT xiaoxiangsheng prognosticvalueoftissueinhibitorofmetalloproteinase2expressioninpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT dongweihua prognosticvalueoftissueinhibitorofmetalloproteinase2expressioninpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT chenyinan prognosticvalueoftissueinhibitorofmetalloproteinase2expressioninpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT xuwei prognosticvalueoftissueinhibitorofmetalloproteinase2expressioninpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT zhutong prognosticvalueoftissueinhibitorofmetalloproteinase2expressioninpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis |